QuarterHawk — Equity ResearchQuarterHawk — Equity Research

AdaptHealth Corp. (AHCO)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
4

Do Nothing: fundamentalScore is 2, below the required floor of 3 - the strategy requires a fundamentally sound company before any bullish entry, so the constructive post-catalyst chart (price above the full 9/21/50-day moving-average stack, MACD +0.36 and expanding, ADX14 26.6 rising, 20-day dollar volume $17.52M) cannot be actioned.

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

AdaptHealth Corp. provides home medical equipment and services across the U.S., specializing in sleep therapy and diabetes management devices. It supports patients transitioning from acute care and offers chronic therapy services.

Fundamental

weak
Fundamental2
Weak fundamentals

The company's financials are weak with declining cash flow, high leverage, and ongoing legal issues.

Home medical equipment provider with positive but deteriorating cash generation: 9M 2026 revenue up 9.7% yet Adjusted EBITDA down 4.2% and free cash flow down to $2.6 million, with FY2026 free-cash-flow guidance cut to $50-75 million. Non-cash goodwill impairments of $457 million over the trailing year drive the GAAP loss, while net debt near $1.9 billion, negative tangible equity and two open False Claims Act investigations keep the risk profile elevated. Debt was refinanced to 2029-2031 with covenant compliance and no going-concern doubt.

Sentiment

fair
Sentiment3
Mixed sentiment

Media sentiment improved post-earnings, but retail sentiment is indeterminate due to access issues.

Dominant catalyst is the 2026-11-03 Q3 2026 print (confidence: announced), which the tape rewarded with a roughly 27% thirty-day move on a revenue beat, organic growth of 12.8%, an adjusted EBITDA beat and raised FY2026 revenue guidance, even though the same cluster carried a $153.99M GAAP net loss from goodwill impairment and an FY2026 free-cash-flow guidance cut to $50-75M from $80-120M; a 2026-11-04 sell-side target raise to $8.86 adds a second, weaker bullish leg. Sentiment delta is a determinate improvement of roughly +0.42 (measured baseline -0.31 to scoring window +0.11), retail is indeterminate (Reddit returned 403 on both permitted queries) and the severe screen is clean, but a moderate red-flag cap applied for conflicting catalyst signals, and the rewarded catalyst is trailing and partially absorbed with no forward-dated driver.

Technical

good
Technical4
Constructive uptrend

The stock is in a short-term uptrend with price above key moving averages and positive momentum indicators.

The chart is technically strong and trend-aligned on the short and intermediate frames: price 7.72 sits above every short/intermediate average (SMA20 6.39, SMA50 6.08, EMA9 6.99, EMA21 6.54, WMA9 7.13, WMA21 6.60, DEMA14 7.23, TEMA14 7.53, daily VWAP 7.59) in a clean ascending stack, MACD has been positive and expanding for five straight sessions (line 0.36, signal 0.18, histogram +0.18), ADX14 has climbed from 17.3 on 2026-10-28 to 26.6 (a genuine, strengthening trend, and with price above the short MAs it is an UP trend, not a down one), and turnover is 3.5x the liquidity floor after the 2026-11-04 range-expansion day. The weak signals are momentum exhaustion and long-term overhead: RSI14 75.63 and Williams %R -4.39 are both pinned at overbought extremes after a +27% thirty-day run, and price remains 14.9% below an SMA200 of 9.07 with SMA50 under SMA200. That combination is a strong setup with one weak signal class, hence 4 rather than 5. No trade is emitted regardless of the chart read because the fundamental override gate blocks any bullish entry (fundamentalScore 2 < required floor of 3); the technical analysis is preserved as analytical reference only.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.